Grifols (NASDAQ:GRFS) Stock Price Up 5.1% – Still a Buy?

Grifols, S.A. (NASDAQ:GRFS) shot up 5.1% during trading on Tuesday . The company traded as high as $8.02 and last traded at $8.01. 514,452 shares were traded during trading, a decline of 72% from the average session volume of 1,834,552 shares. The stock had previously closed at $7.62.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Price Performance

The stock’s 50 day simple moving average is $8.37 and its 200-day simple moving average is $8.10. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm has a market cap of $5.31 billion, a price-to-earnings ratio of 7.96 and a beta of 0.43.

Institutional Trading of Grifols

Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares during the last quarter. Signaturefd LLC lifted its stake in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,153 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Grifols during the 2nd quarter worth approximately $89,000. HighTower Advisors LLC increased its stake in shares of Grifols by 12.5% in the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,546 shares during the last quarter. Finally, Tidal Investments LLC purchased a new position in Grifols during the third quarter worth about $147,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.